IFNB1 and myeloid sarcoma: As an immunoregulatory subpopulation playing a protective role in MS [6, 25] and given the fact that, after a year [8] or two [9] of IFN-β treatment it appears to expand, a higher circulating frequency of this subpopulation was expected.